Rates of Seroprotection against Vaccine-Preventable Infectious Diseases in HIV-Exposed and -Unexposed Malawian Infants.
Africa
HIV in utero-exposition
Haemophilus influenzae type B
IgG protective levels
Streptococcus pneumoniae
hepatitis B
infants
vaccine-preventable diseases
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
14 Jul 2023
14 Jul 2023
Historique:
received:
26
06
2023
revised:
11
07
2023
accepted:
13
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The evaluation of seroprotection rates against vaccine-preventable infectious diseases allows for the identification of risk populations. HIV-exposed infants, even if not infected with HIV, have higher morbidity and mortality in comparison to unexposed counterparts. The aim of this study was to compare the specific IgG levels against Blood samples from 62 infants, 49 HIV-exposed, uninfected (HEU), and born to women living with HIV and 13 HIV-unexposed and uninfected (HUU), were collected at 6 months, and specific IgG levels were determined using ELISA tests. The antibody levels against HiB, HBV, and Spn were similar in the two groups. At six months, all HUU infants and 81.6% of HEU infants showed seroprotective levels against HiB, while a percentage of protection varying from 80.6 to 84.6% was observed for HBV and Spn regardless of HIV exposure. Only 59.2% of HEU and 69.2% of HUU infants showed antibody protection against all three pathogens. These results indicate similar rates of seroprotection among HEU and HUU infants but also suggest that a consistent fraction of infants received incomplete vaccinations. Strategies to enforce participation in immunization programs in Malawi should be a health priority.
Sections du résumé
BACKGROUND
BACKGROUND
The evaluation of seroprotection rates against vaccine-preventable infectious diseases allows for the identification of risk populations. HIV-exposed infants, even if not infected with HIV, have higher morbidity and mortality in comparison to unexposed counterparts. The aim of this study was to compare the specific IgG levels against
METHODS
METHODS
Blood samples from 62 infants, 49 HIV-exposed, uninfected (HEU), and born to women living with HIV and 13 HIV-unexposed and uninfected (HUU), were collected at 6 months, and specific IgG levels were determined using ELISA tests.
RESULTS
RESULTS
The antibody levels against HiB, HBV, and Spn were similar in the two groups. At six months, all HUU infants and 81.6% of HEU infants showed seroprotective levels against HiB, while a percentage of protection varying from 80.6 to 84.6% was observed for HBV and Spn regardless of HIV exposure. Only 59.2% of HEU and 69.2% of HUU infants showed antibody protection against all three pathogens.
CONCLUSIONS
CONCLUSIONS
These results indicate similar rates of seroprotection among HEU and HUU infants but also suggest that a consistent fraction of infants received incomplete vaccinations. Strategies to enforce participation in immunization programs in Malawi should be a health priority.
Identifiants
pubmed: 37513785
pii: pathogens12070938
doi: 10.3390/pathogens12070938
pmc: PMC10383556
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italy Independent Activity in the scope of EDCTP2
ID : PSIA 2019-2072
Organisme : Italian Agency for Cooperation and Development through the Global Fund 5% Initiative
ID : AID 011141/03/04
Références
Pediatr Neonatol. 2019 Dec;60(6):623-633
pubmed: 31040068
BMC Res Notes. 2019 Feb 14;12(1):84
pubmed: 30764874
Hum Vaccin Immunother. 2021 Feb 1;17(2):397-399
pubmed: 32574099
Hum Vaccin Immunother. 2017 May 4;13(5):972-980
pubmed: 28281907
Vaccine. 2013 Mar 15;31(12):1560-8
pubmed: 23196207
Int J STD AIDS. 2023 Jan;34(1):54-61
pubmed: 36285600
J Allergy Clin Immunol. 2011 Jun;127(6):1410-1
pubmed: 21376379
J Infect Dis. 2022 Sep 28;226(7):1243-1255
pubmed: 35403683
Pediatr Infect Dis J. 2021 May 1;40(5S):S40-S46
pubmed: 34042910
Vaccine. 2022 Jan 3;40(1):141-150
pubmed: 34794824
BMJ Glob Health. 2021 May;6(5):
pubmed: 34006521
AIDS. 2021 Nov 15;35(14):2327-2339
pubmed: 34324450
Am J Trop Med Hyg. 2022 Dec 19;108(2):394-402
pubmed: 36535249
J Infect Dis. 2010 Aug 15;202(3):355-61
pubmed: 20583920
BMC Public Health. 2022 Mar 17;22(1):520
pubmed: 35296298
AIDS Care. 2021 Dec;33(12):1595-1602
pubmed: 33615906
AIDS. 2014 Jun 19;28(10):1421-30
pubmed: 24785950
AIDS. 1994 Sep;8(9):1281-4
pubmed: 7802981
AIDS. 2014 Feb 20;28(4):531-41
pubmed: 24468996
Clin Infect Dis. 2020 Jul 11;71(2):332-339
pubmed: 31504291
PLoS Med. 2018 Mar 30;15(3):e1002547
pubmed: 29601570
Clin Vaccine Immunol. 2013 Jan;20(1):33-8
pubmed: 23114697
BMJ Open. 2022 Feb 8;12(2):e050188
pubmed: 35135765
J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):1-8
pubmed: 31408450
Int Health. 2022 May 2;14(3):250-259
pubmed: 34153106
PLoS One. 2013 Jul 19;8(7):e68950
pubmed: 23894379
BMC Public Health. 2016 Dec 9;16(1):1240
pubmed: 27938363
BMC Public Health. 2020 Nov 30;20(1):1821
pubmed: 33256655
J Infect Dis. 2022 Oct 17;226(8):1441-1450
pubmed: 35668706